Edward M. Kaye
2023 - Stoke Therapeutics
In 2023, Edward M. Kaye earned a total compensation of $3.5M as Chief Executive Officer at Stoke Therapeutics, a 39% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $309,814 |
|---|---|
| Option Awards | $1,285,008 |
| Salary | $625,887 |
| Stock Awards | $1,299,300 |
| Other | $13,201 |
| Total | $3,533,210 |
Kaye received $1.3M in stock awards, accounting for 37% of the total pay in 2023.
Kaye also received $309.8K in non-equity incentive plan, $1.3M in option awards, $625.9K in salary and $13.2K in other compensation.
Rankings
In 2023, Edward M. Kaye's compensation ranked 211th out of 2,238 executives tracked by ExecPay. In other words, Kaye earned more than 90.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 211 out of 2,238 | 91st |
Division Manufacturing | 111 out of 1,216 | 91st |
Major group Chemicals And Allied Products | 75 out of 683 | 89th |
Industry group Drugs | 73 out of 654 | 89th |
Industry Pharmaceutical Preparations | 48 out of 470 | 90th |
Source: SEC filing on April 23, 2024.
Kaye's colleagues
We found two more compensation records of executives who worked with Edward M. Kaye at Stoke Therapeutics in 2023.